Movement Alert｜HBM HOLDINGS-B Falls 5.31% in Regular Trading, Biotech Sector Broadly Weakens as Prior Gains Retrace

Market Focus09-24 10:24

On September 24, HBM HOLDINGS-B fell 5.31% in regular trading to HKD 14.44, with turnover of approximately HKD 37.95 million. The decline came amid broad-based selling pressure across the biotechnology sector, compounded by profit-taking following a series of recent positive catalysts.

The biotech sector experienced widespread weakness, with REMEGEN down 6.22%, AKESO down 3.95%, 3SBIO down 3.94%, INNOVENT BIO down 3.72%, and BEONE MEDICINES down 1.56%, reflecting broadly dampened sector sentiment. For HBM HOLDINGS-B specifically, the stock had rallied sharply in recent sessions — rising 7.4% on September 21 and gaining approximately 5% on September 17 — driven by its subsidiary Nona Biosciences unveiling HCAbLM, the worlds first language model trained on fully human heavy-chain-only antibodies, as well as robust H1 results showing revenue of USD 122 million, up 20.9% year-over-year. With these catalysts now largely priced in, selling pressure intensified as investors locked in gains amid the sector-wide pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175127947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175127947","market":"us","top_or_hot":-1,"title":"Movement Alert｜HBM HOLDINGS-B Falls 5.31% in Regular Trading, Biotech Sector Broadly Weakens as Prior Gains Retrace","media":"Market Focus","content":"<p><p>On September 24, HBM HOLDINGS-B fell 5.31% in regular trading to HKD 14.44, with turnover of approximately HKD 37.95 million. The decline came amid broad-based selling pressure across the biotechnology sector, compounded by profit-taking following a series of recent positive catalysts.</p><p>The biotech sector experienced widespread weakness, with REMEGEN down 6.22%, AKESO down 3.95%, 3SBIO down 3.94%, INNOVENT BIO down 3.72%, and BEONE MEDICINES down 1.56%, reflecting broadly dampened sector sentiment. For HBM HOLDINGS-B specifically, the stock had rallied sharply in recent sessions — rising 7.4% on September 21 and gaining approximately 5% on September 17 — driven by its subsidiary Nona Biosciences unveiling HCAbLM, the worlds first language model trained on fully human heavy-chain-only antibodies, as well as robust H1 results showing revenue of USD 122 million, up 20.9% year-over-year. With these catalysts now largely priced in, selling pressure intensified as investors locked in gains amid the sector-wide pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HBM HOLDINGS-B Falls 5.31% in Regular Trading, Biotech Sector Broadly Weakens as Prior Gains Retrace</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HBM HOLDINGS-B Falls 5.31% in Regular Trading, Biotech Sector Broadly Weakens as Prior Gains Retrace\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, HBM HOLDINGS-B fell 5.31% in regular trading to HKD 14.44, with turnover of approximately HKD 37.95 million. The decline came amid broad-based selling pressure across the biotechnology sector, compounded by profit-taking following a series of recent positive catalysts.</p><p>The biotech sector experienced widespread weakness, with REMEGEN down 6.22%, AKESO down 3.95%, 3SBIO down 3.94%, INNOVENT BIO down 3.72%, and BEONE MEDICINES down 1.56%, reflecting broadly dampened sector sentiment. For HBM HOLDINGS-B specifically, the stock had rallied sharply in recent sessions — rising 7.4% on September 21 and gaining approximately 5% on September 17 — driven by its subsidiary Nona Biosciences unveiling HCAbLM, the worlds first language model trained on fully human heavy-chain-only antibodies, as well as robust H1 results showing revenue of USD 122 million, up 20.9% year-over-year. With these catalysts now largely priced in, selling pressure intensified as investors locked in gains amid the sector-wide pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1175127947","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175127947","pubTimestamp":1790216641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, HBM HOLDINGS-B fell 5.31% in regular trading to HKD 14.44, with turnover of approximately HKD 37.95 million. The decline came amid broad-based selling pressure across the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"走势警报|HBM HOLDINGS-B 在常规交易中下跌 5.31%，生物技术板块普遍走弱，此前涨幅回落","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"On September 24, HBM HOLDINGS-B fell 5.31% in regular trading to HKD 14.44, with turnover of approximately HKD 37.95 million. The decline came amid broad-based selling pressure across the biotechnology sector, compounded by profit-taking following a series of recent positive catalysts.The biotech sector experienced widespread weakness, with REMEGEN down 6.22%, AKESO down 3.95%, 3SBIO down 3.94%, INNOVENT BIO down 3.72%, and BEONE MEDICINES down 1.56%, reflecting broadly dampened sector sentiment. For HBM HOLDINGS-B specifically, the stock had rallied sharply in recent sessions — rising 7.4% on September 21 and gaining approximately 5% on September 17 — driven by its subsidiary Nona Biosciences unveiling HCAbLM, the worlds first language model trained on fully human heavy-chain-only antibodies, as well as robust H1 results showing revenue of USD 122 million, up 20.9% year-over-year. With these catalysts now largely priced in, selling pressure intensified as investors locked in gains amid the sector-wide pullback.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175127947","isCrawlerRequest":true}